Protein Kinase A Regulatory Subunits in Human Adipose Tissue

Decreased R2B Expression and Activity in Adipocytes From Obese Subjects

Giovanna Mantovani,1 Sara Bondioni,1 Luisella Alberti,2 Luisa Gilardini,2 Cecilia Invitti,2 Sabrina Corbetta,3 Marco A. Zappa,4 Stefano Ferrero,5 Andrea G. Lania,1 Silvano Bosari,5 Paolo Beck-Peccoz,1 and Anna Spada1

OBJECTIVE—In human adipocytes, the cAMP-dependent pathway mediates signals originating from β-adrenergic activation, thus playing a key role in the regulation of important metabolic processes, i.e., lipolysis and thermogenesis. Cyclic AMP effects are mainly mediated by protein kinase A (PKA), whose R2B regulatory isof orm is the most expressed in mouse adipose tissue, where it protects against diet-induced obesity and fatty liver development. The aim of the study was to investigate possible differences in R2B expression, PKA activity, and lipolysis in adipose tissues from obese and nonobese subjects.

RESEARCH DESIGN AND METHODS—The expression of the different PKA regulatory subunits was evaluated by immunohistochemistry, Western blot, and real-time PCR in subcutaneous and visceral adipose tissue samples from 20 nonobese and 67 obese patients. PKA activity and glycerol release were evaluated in total protein extract and adipocytes isolated from fresh tissue samples, respectively.

RESULTS—Expression techniques showed that R2B was the most abundant regulatory protein, both at mRNA and protein level. Interestingly, R2B mRNA levels were significantly lower in both subcutaneous and visceral adipose tissues from obese than nonobese patients and negatively correlated with BMI, waist circumference, insulin levels, and homeostasis model assessment of insulin resistance. Moreover, both basal and stimulated PKA activity and glycerol release were significantly lower in visceral adipose tissue from obese patients than nonobese subjects.

CONCLUSIONS—Our results first indicate that, in human adipose tissue, there are important BMI-related differences in R2B expression and PKA activation, which might be included among the multiple determinants involved in the different lipolytic response to β-adrenergic activation in obesity. Diabetes 58: 620–626, 2009

Cyclic AMP is implicated in the regulation of a variety of cell functions that are, at least in part, related to protein phosphorylation through the activation of protein kinase A (PKA). In addition to the control of differentiated functions, such as motility, secretion, metabolism, differentiation, synaptic transmission, and ion channel activities, cAMP inhibits or stimulates cell proliferation depending on the cell type. In human adipocytes, the cAMP-dependent pathway mediates signals originating from the activation of β-adrenergic receptors, thus playing a key role in the regulation of important metabolic processes, such as lipolysis and thermogenesis. Cyclic AMP effects are mainly mediated by PKA, a tetrameric enzyme composed of two catalytic subunits associated with two regulatory subunits. There are four different regulatory subunit genes and proteins (R1A, R1B, R2A, and R2B) expressed with a tissue-specific pattern and exerting distinct roles in cell differentiation and growth control (1). Dramatic changes in the proportion of the two PKA regulatory subunits, R1 and R2, occur during ontogenic development, differentiation processes, and neoplastic transformation, indicating distinct roles for these isoenzymes in cell homeostasis and growth control (2,3). In the past few years, many studies seem to indicate that signaling via PKA plays an important role in regulating metabolism and body weight (4). In particular, the R2B isoform has been demonstrated to be, in mice, the most expressed in three tissues known to regulate energy homeostasis, i.e., brown adipose tissue, white adipose tissue, and brain (4,5). In general, the activation of the holoenzyme PKA in fat is now thought to decrease obesity, as demonstrated in both genetically obese (ob/ob) (6,7) and diet-induced obese mice (8). As far as the R2B subunit is concerned, studies in mice lacking this specific PKA subunit have revealed an unexpected role for this protein in regulating energy balance (5). R2B knockout mice (RⅢF→/→) remain remarkably lean, even when challenged with a high-fat diet (5). These animals have increased metabolic activity, manifested by increases in body temperature, uncoupling protein 1 concentration, and lipid hydrolysis. Biochemical studies have shown that loss of R2B is compensated by the increased R1A regulatory...
subunit, which is more sensitive to cAMP activation and results in a net increase in basal PKA activity (9).

In contrast to this increasing knowledge in mice, little is known about the differential role played by the different PKA regulatory subunits in humans. Two studies from the same group have described lower R2B levels in adipose tissues from 10 normal-weight women affected with polycystic ovary syndrome (PCOS) when compared with 13 matched control women and associated this event with lipolytic catecholamine resistance and insulin resistance in these patients (10,11). We present the first study evaluating the relative expression of the different PKA isoforms in a large series of human adipose tissues. Our results indicate important BMI-related differences in R2B expression and PKA activation, which might play a role in the different lipolytic response to β-adrenergic activation in obese and nonobese subjects.

RESEARCH DESIGN AND METHODS

Patients, adipose tissues, and cell cultures. The study included 87 human subcutaneous and visceral adipose tissue samples from 67 obese patients (BMI >30 kg/m²) and 20 age- and sex-matched nonobese subjects (BMI <30 kg/m²), collected during bariatric surgery and abdominal surgical procedure for benign disease (elective cholecystectomy), respectively. The subjects were all Caucasians and, aside from the surgery indication, were all apparently healthy, with no history of alcohol overconsumption. No patient had overt diabetes or lipodystrophia and no one was under antihypertensive treatment. The study was approved by the local ethics committee of Fondazione Ospedale Maggiore Policlinico IRCCS, Milan. All subjects gave their informed consent before participation.

Small sample fragments were fixed for immunohistochemistry (IHC), part of the tissues was digested with collagenase type II (Sigma-Aldrich, Milan, Italy) for the isolation of adipocytes, while the remaining tissue was quickly frozen for subsequent molecular analysis. Adipocytes separation from preadipocytes and other cell types was based on cellular dimension and density. Briefly, adipocytes (0.1–1.5 mm) were digested in an albumin solution containing collagenase (DMEM F12 containing Hepes 15 mmol/l, Biotin 33 mmol/l, BSA 2%, collagenase type II 750 μg/ml, antibiotics; all reagents from Sigma-Aldrich) at 37°C for 2 h. The digested tissue was passed on a 100-μm filter (nylon cell strainer; BD Transduction Laboratories, Lexing- ton, U.K.) to eliminate undigested material. The obtained cell suspension was centrifuged at 15 min. In this centrifugation step, preadipocytes are pelleted at the bottom of the tube, while adipocytes are found on the surface as a ring due to their low density. At this step, the adipocyte ring is transferred to a new tube, and isolated adipocytes are ready to be used for subsequent analysis. Pelletted preadipocytes are resuspended in culture medium (DMEM F12 containing Hepes 15 mmol/l, Biotin 33 mmol/l, BSA 2%, collagenase type II 750 μg/ml, FBS 10%, antibiotics) and passed on a 40-μm filter to eliminate eventually remaining adipocytes and other cell types on the basis of their different diameter. After filtration, the cell suspension is centrifugated (1,000 rpm, 15 min), and pelletted preadipocytes are resuspended in culture media and used for subsequent experiments.

Immunohistochemistry. Adipose tissue samples were processed for IHC, as previously reported (10). Specific monoclonal antibodies for PKA R1A, PKA R2A, and PKA R2B were used under the conditions specified by the manufacturer (BD Transduction Laboratories, Lexington, U.K.). Antigen-antibody detection was performed using the DAKO ChemMate En Vision detection kit (DAKO A/S, Glostrup, Denmark) according to the manufacturer’s instructions. Sections were stained with 3,3′-diaminobenzidine substrate, counterstained with Meyer hematoxylin and slides prepared for light microscopy examination, as previously reported (12). Negative controls were obtained by oculating the primary antibody or by using an unrelated mouse monoclonal antibody.

Western blot. Western blotting was performed as previously described (12) on total protein extracts from 40 visceral adipose tissue samples (20 from nonobese and 20 from obese subjects). Briefly, total proteins extracted from adipose tissue samples were quantified using the BCA assay protein kit (Pierce, Rockford, IL), and 20 μg was resolved by 10% SDS-PAGE and transferred onto nitrocellulose membrane (Bio-Rad Laboratories, Hercules, CA). PKA R1A, PKA R2B, and PKA R2A were detected using the same specific monoclonal antibodies used for IHC and detected by the chemiluminescent method, and the resulting bands were evaluated by imaging densitometer (BioRad GS-670) (12). Experiments were repeated at least twice.

mRNA quantitative analysis. Total RNA was isolated from tissue specimens using a commercial kit (Qiagen Rneasy mini kit) according to the manufacturer’s instructions, and 200 ng RNA was reverse-transcribed (Superscript Invitrogen S.R.L., Italy). PKA R1A, PKA R2A, and PKA R2B mRNA levels were evaluated by real-time quantitative RT-PCR based on TaqMan methodology, using a ready-to-use assay (identification numbers Hs00267597_m1, Hs00177760_m1, and Hs00176966_m1, respectively; Assay-on-Demand Gene Expression Products, Applied Biosystems, Foster City, CA), according to the manufacturer’s instructions, and the ABI Prism 7700 Sequence Detection System (Applied Biosystems). PKA R1A, R2A, and R2B mRNA expression were determined applying the ΔΔct method, as previously described (12). To normalize the amount of total RNA added to each reaction mixture, we quantified the internal RNA control the GUSB mRNA (14). The level of CD68 mRNA was also evaluated to quantify blood contamination and inflammatory infiltration. Similar results were obtained with or without normalization with CD68 mRNA levels, thus indicating absent or poor contamination in all samples.

PKA activity. PKA activity was measured, as previously reported (12), using a nonradioactive PKA kinase activity assay kit (Stressgen, Victoria BC, Canada) in 1 μg protein extracts from human subcutaneous and visceral adipose tissue samples (20 nonobese and 20 obese subjects). The assay is based on a solid-phase enzyme-linked immunosorbent assay that uses a specific synthetic peptide as a substrate for PKA (kepemptide) and a polyclonal antibody that recognizes the phosphorylated form of the substrate. PKA activity reflects the enzymatic activity after stimulation with 5 μmol/l cAMP, free PKA activity represents basal activity in the absence of stimulation, and total PKA activity is calculated as the difference between cAMP-stimulated PKA and the PKA inhibited by the protein kinase inhibitor (PKI) (5 μmol/l). Data obtained from different assays were normalized by including the same control sample in each experiment.

Glyceral release. Adipocytes were isolated from 40 visceral and subcutane- ous tissue samples from 39 men and 13 women from patients under 540 mm is directly proportional to the glycerol concentration of the sample and was expressed as SD.

RESULTS

PKA regulatory subunit expression in human subcutaneous and visceral adipose tissues. Immunohistochemistry performed on human adipose tissue samples from both nonobese and obese subjects included in the study showed a strong immunopositivity for PKA R2B, whereas the other PKA regulatory subunits analyzed (R2A and R1A) were either absent or expressed at very low levels (Fig. 1A).

Western blot analysis was performed on total protein extracts from 40 visceral adipose tissue samples (20 from

DIABETES, VOL. 58, MARCH 2009 621

G. MANTOVANI AND ASSOCIATES
nonobese and 20 from obese subjects). This approach confirmed the prevalence of the PKA R2B subunit over R1A and R2A subunits, which were either absent or detected at extremely low levels (Fig. 1C). Moreover, quantification of the resulting bands showed that PKA R2B protein was significantly lower in adipose tissues from obese patients compared with those from nonobese patients \( (P < 0.01, \text{Fig. 1B and C}) \).

The transcriptional level of PKA R subunits was analyzed by real-time RT-PCR in total RNA extracted from all the adipose tissue samples included in the study. This analysis confirmed that in all samples, PKA R2B was the predominant PKA regulatory subunit also at the mRNA level, whereas PKA R1A and particularly PKA R2A were expressed at lower levels. However, mRNA levels of the three regulatory subunits were significantly lower in obese patients than in nonobese subjects \( (P < 0.00005; \text{PKA 2A: } P < 0.01; \text{PKA 2B: } P < 0.0001) \). In particular, the reduced expression of PKA R2B and R1A subunit mRNA in obese versus nonobese subjects was strongly significant in both subcutaneous \( (\text{PKA 2B: } P < 0.001; \text{PKA 1A: } P < 0.001) \) and visceral \( (\text{PKA 2B: } P < 0.01; \text{PKA 1A: } P < 0.05) \) adipose tissue samples, whereas PKA R2A expression was extremely low in all samples, with a tendency to be lower in those from obese patients \( (P = 0.06) \) (Fig. 2). When comparing the expression level of PKA R in visceral versus subcutaneous adipose tissue, no difference in PKA R expression was observed in samples from nonobese subjects, whereas visceral adipocytes from obese patients expressed higher levels of PKA R2B and R1A when compared with the corresponding subcutaneous adipose tissue samples (adipose tissue from obese versus nonobese subjects: \( \ast P < 0.01; \#P < 0.05; \#P < 0.001 \)).

FIG. 1. A: Immunostaining for the three PKA regulatory subunits (R1A, R2A, and R2B) performed in a human subcutaneous adipose tissue, as a representative example (upper panels). Similar data were obtained in the other 84 subcutaneous and visceral samples (from obese and nonobese subjects). All photomicrographs are shown at an original magnification of \( \times25 \). B: PKA R2B protein representative Western blot analysis performed in human subcutaneous adipose tissue samples from four obese and four nonobese subjects, as representative examples of the 40 samples analyzed. C: Immunoblots were measured by an imaging densitometer and the values are expressed in arbitrary units. Data were normalized through GAPDH antibody hybridization. (Please see http://dx.doi.org/10.2337/db08-0585 for a high-quality digital representation of this figure.)

FIG. 2. PKA regulatory subunit (R1A, R2A, and R2B) mRNA expression in human adipose tissue from obese and nonobese subjects as assessed by real-time PCR. Data are expressed as mRNA relative quantities. Overall, obese subjects express significantly lower levels of R1A and R2B subunit mRNA than nonobese subjects, and a similar expression pattern is observed both in visceral (A) and subcutaneous (B) adipose tissue samples (adipose tissue from obese versus nonobese subjects: \( \ast P < 0.01; \#P < 0.05; \#P < 0.001 \)).
TABLE 1
Clinical data of obese and nonobese subjects included in this study

|                | Obese   | Nonobese | P  |
|----------------|---------|----------|----|
| n              | 67      | 20       |    |
| Age (years)    | 46.4 ± 11.7 | 41.9 ± 10.2 | NS |
| Sex (F:M)      | 53:14   | 14:6     | NS |
| BMI (kg/m²)    | 37.07 ± 5.3 | 22.8 ± 3.9 | <0.001 |
| Waist circumference (cm) | 116 ± 12.6 | 88.3 ± 8.2 | <0.001 |
| Systolic blood pressure (mmHg) | 143 ± 18 | 122 ± 21 | NS |
| Diastolic blood pressure (mmHg) | 94 ± 13 | 83 ± 9 | NS |
| Plasma insulin (µU/l) | 18 ± 10 | 11.5 ± 6 | 0.05 |
| Plasma glucose (mmol/l) | 5.2 ± 2.4 | 4.9 ± 0.8 | NS |
| HOMA-IR        | 3.9 ± 1.1 | 2.4 ± 0.4 | <0.01 |

Data are means ± SD unless otherwise indicated.

(PKA 1A and PKA 2B: 2.54 ± 1.5 and 3.67 ± 0.9 in subcutaneous vs. 4.82 ± 1.8 and 8.72 ± 2.2 in visceral adipose tissue, \( P = 0.013 \) and \( P = 0.019 \), respectively).

**Correlation between PKA R2B mRNA levels and clinical parameters.** The main clinical data of obese and nonobese patients included in this study are summarized in Table 1. We correlated the expression of PKA regulatory subunits with clinical parameters. In particular, following the demonstration of low R2B protein levels in patients with PCOS (10,11), a syndrome characterized by insulin resistance, we searched for correlations between PKA regulatory subunit expression and insulin levels, as well as HOMA-IR as a surrogate marker of insulin resistance. Statistical analysis demonstrated that PKA R2B expression was strongly negatively correlated to BMI, waist circumference, insulin levels, and HOMA-IR (subcutaneous: \( r = -0.280 \), \( r = -0.296 \), \( r = -0.269 \), \( r = -0.255 \), respectively; \( P < 0.01 \); visceral: \( r = -0.298 \), \( r = -0.267 \), \( r = -0.240 \), \( r = -0.245 \), respectively; \( P < 0.01 \)), with these last two correlations being independent of BMI (Fig. 3). No correlation was observed with age and/or the presence or the absence of menopause, and no difference was detected between males and females in the two groups (obese and nonobese).

**PKA and lipolytic activity in human subcutaneous and visceral adipose tissues.** PKA activity was evaluated in 1 µg total protein extracts from both visceral and subcutaneous adipose tissue samples of 20 nonobese and 20 obese subjects. Basal PKA activity was reduced in visceral and subcutaneous protein samples from adipocytes of obese subjects compared with what was observed in nonobese subjects. However, this difference was statistically significant only for visceral adipose tissue (visceral: \( P = 0.017 \); subcutaneous: \( P = 0.464 \)).

In all the samples analyzed, enzymatic PKA activity was significantly stimulated by cAMP treatment. The same results were obtained after treatment with 8-Cl-cAMP, a cAMP analog able to selectively activate PKA type 2 (2), whereas the addition of the PKA inhibitor PKI (5 µmol/l) significantly reduced cAMP-stimulated activity, as expected (Fig. 4). Interestingly, the cAMP- and 8-Cl-cAMP-induced stimulation of PKA activity in proteins from visceral adipose tissue of obese patients was significantly lower than that observed in samples from nonobese patients, whereas the difference did not reach statistical significance in subcutaneous adipose tissues (Fig. 4).

Lipolytic activity was measured by evaluating the quantity of glycerol released by adipocytes in culture medium. Glycerol release was measured both at basal level and after stimulation of β-adrenergic receptor by isoproterenol. 

![FIG. 4. PKA activity measured (relative fluorescence units [RFU]) in cell extracts from visceral (A) and subcutaneous (B) adipose tissue samples from obese and nonobese patients. cAMP and 8-Cl-cAMP increased PKA activity both in obese and nonobese subject adipocytes, with this stimulation being inhibited by the PKA inhibitor PKI. Basal and stimulated PKA activity was significantly lower in visceral adipose tissue from obese patients than in samples from nonobese subjects. *P < 0.05 vs. basal; #P < 0.05 vs. cAMP stimulated; §§P < 0.05 vs. nonobese subjects.](image-url)
or after stimulation of PKA R2B by 8-Cl-cAMP. The stimulation of cAMP pathway by isoproterenol or 8-Cl-cAMP was able to induce an increase in glycerol release both in visceral and subcutaneous adipocytes from obese and nonobese subjects \((P < 0.05\) vs. basal). However, glycerol release was lower in adipocytes from obese subjects, compared with nonobese subjects, both at the basal level and after treatment with isoproterenol or 8-Cl-cAMP, with these data being statistically significant only in visceral tissue (Fig. 5). Finally, no difference in basal glycerol release between subcutaneous and visceral adipocytes was observed, whereas the effects of cAMP and 8-Cl-cAMP on lipolysis were significantly higher in visceral than subcutaneous adipose tissue from obese patients than in samples from nonobese subjects. \(*P < 0.05\) vs. basal; \(\delta P < 0.05\) vs. nonobese.

A positive correlation was found between PKA R2B mRNA expression and basal PKA activity and isoproterenol-stimulated glycerol release in visceral fat \((r = 0.430, P = 0.009, \text{and} r = 0.398, P = 0.002, \text{respectively})\). RFU, relative fluorescence units.

DISCUSSION

Obesity is rapidly increasing in industrialized countries and, with very few exceptions, the molecular mechanisms underlying the predisposition to become obese are largely unknown. In both white and brown adipocytes, cAMP and the cAMP-dependent PKA are key regulators of lipolysis, the most important process determining fat storage or mobilization (4). Data present in the literature to date indicate that, at least in mice, among the different subunits constituting the PKA holoenzyme, PKA R2B is the key regulatory subunit in adipose tissue (4,5,9,15–20). Interestingly, R2B expression is limited to a few tissues known to regulate energy homeostasis, i.e., the white and brown adipose tissue and the brain. Studies in R2B knockout mice revealed an unexpected role for this protein in regulating energy balance, since these animals remain remarkably lean even when challenged with a high-fat diet (5).

Despite this increasing amount of data on murine adipose tissue, and although many groups, including ours, have clearly demonstrated distinct and cell-specific roles for the different PKA isoenzymes in the regulation of growth control (1,2,12,13,21), very little is known about the differential role played by the different PKA regulatory subunits in human fat tissue. In this study, we evaluated the possible differences in R2B expression, PKA activity, and lipolysis in subcutaneous and visceral adipose tissue samples from a large number of obese and nonobese subjects. Immunohistochemistry demonstrated a strong immunoreactivity for the R2B protein in all fat tissues included in our study, whereas the other PKA regulatory subunits analyzed (R2A and R1A) were expressed at very low levels. This was true in visceral as well as in subcutaneous adipose tissue, and similar data were obtained by Western blot analysis. This observation first demonstrates that PKA regulatory subunit expression in human adipose tissue is similar to what was previously observed in murine adipocytes and supports the hypothesis that PKA R2B expression is specific for adipose tissue and few other cell types (5,9).

Western blot analysis, which better allows the quantification of protein expression than immunohistochemistry, showed that PKA R2B protein expression was dramatically reduced in adipose tissues from obese patients compared with those from nonobese subjects. This observation lead us to investigate the pattern of expression also at the mRNA level. In contrast to what was observed at the protein level, mRNA of the three subunits was detected in human adipose tissue samples from both obese and nonobese subjects. mRNA expression and basal PKA activity and isoproterenol-stimulated glycerol release were significantly lower in visceral adipose tissue from obese patients than in samples from nonobese subjects \((r = 0.430, P = 0.009, \text{and} r = 0.398, P = 0.002, \text{respectively})\). RFU, relative fluorescence units.
ancy between R1A mRNA and protein expression suggests the existence of a high rate of protein instability and degradation, as already demonstrated for this subunit by us and others in other cell systems (12,22). Interestingly and similarly to Western blot data, mRNA levels of the three regulatory subunits were significantly reduced in obese subjects if compared with nonobese subjects. In particular, the difference in the expression of PKA R2B and R1A subunit mRNA between obese and nonobese subjects was strongly significant in both subcutaneous and visceral adipose tissue samples, whereas the difference in PKA R2A expression did not reach statistical significance. In agreement with the restricted expression of the R1B gene (23), this transcript was absent in subcutaneous and visceral adipose tissues from obese and nonobese subjects (G.M., personal observations).

We then tried to correlate the expression of PKA regulatory subunits with clinical parameters, particularly insulin levels and HOMA-IR. We chose HOMA-IR as a surrogate marker of insulin resistance, since an oral glucose tolerance test was indicated and performed only in obese patients. Indeed, PKA R2B expression was negatively correlated to BMI and waist circumference, a clinical parameter strongly associated with visceral obesity. Moreover, R2B mRNA levels were also negatively correlated with insulin levels and HOMA-IR, with these correlations being independent of BMI. These findings are in agreement with the only data present in the literature on PKA expression and function in humans that indicate low levels of PKA R2B in normal-weight women affected with PCOS when compared with matched control women, with this defect being associated with lipolytic catecholamine resistance and insulin resistance in these patients (10,11). Taking into account that the PRKAR2B promoter has SP-1 transcription factor binding sites, it is tempting to speculate that insulin might act on these sites to positively regulate PRKAR2B transcription (24).

The functional impact of the differential expression of PKA regulatory subunits in adipose tissues from nonobese and obese patients was assessed by evaluating PKA activity and glycerol release in the same samples. Although both basal and cAMP-stimulated PKA activity were lower in visceral and subcutaneous protein samples from obese subjects, compared with what was observed in samples from nonobese patients, these differences were statistically significant only in visceral adipose tissue. Interestingly, a similarly reduced PKA activity in adipose tissue from obese patients was observed after stimulation with a cAMP analog able to selectively activate R2 subunits (8-Cl-cAMP), suggesting that the low levels of PKA R2B mRNA and protein detected in these tissues are indeed associated with a lower PKA activity. Similarly, glycerol release measured at basal level and after stimulation of β-adrenergic receptor by isoprenalol was significantly reduced in visceral adipocytes from obese patients compared with nonobese subjects. Stimulation with the R2-selective analog 8-Cl-cAMP induced a significant increase in lipolysis in samples from both obese and nonobese subjects, with this increase being significantly lower in visceral adipose tissue from obese patients. Taken together, these data further support the correlation between real-time PCR and Western blot data and the activation of the cAMP/PKA pathway and lipolysis. At the moment, these data do not allow any speculation on the role played in this circuit by A-kinase anchoring proteins, specific anchor proteins that recruit the PKA holoenzyme close to its substrate/effector proteins, thus directing and modulating PKA activation.

Our data seem to be partially at variance with the data in PCOS patients previously reported, in whom the decreased expression of R2B in visceral fat cells obtained from nonobese PCOS patients was associated with a twofold increase in R1A and in the catalytic subunit and a consequent twofold increase in catecholamine-induced adipocyte lipolysis (10), whereas the reduction of R2B in subcutaneous fat was associated with a reduced lipolytic responsiveness and sensitivity, mostly due to decreased expression of the β2-adrenergic receptor (11). However, in the present study, PKA activity and glycerol release were investigated by selectively activating R2 subunits, thus providing novel evidence for a specific functional impact of R2B loss in adipocytes, not related to adrenoreceptor downregulation.

In mice, the loss of R2B revealed an unexpected role for this protein in regulating energy balance (5). In particular, the absence of this protein is compensated by an increase in the R1A subunit, which is more sensitive to cAMP activation and results in a net increase in basal PKA activity, leading to an increase in metabolic activity, body temperature, and lipid hydrolysis (5,9). In humans, our work indicates that the reduction of R2B that accompanies obesity is not associated with an increase in R1A. Nevertheless, it seems likely that the higher R2B levels found in nonobese subjects may account, alone, for the PKA activity required for lipolysis activation in physiological conditions.

The regulation of human fat cell lipolysis is complex and, in many ways, species unique. Catecholamines influence lipolysis through four different adrenoreceptor subtypes, and there are profound regional variations in adipocyte lipolysis leading to more release of fatty acids from the visceral than subcutaneous adipose tissue during hormone stimulation (25–27). These regional variations in lipolysis have been demonstrated to be further enhanced in obesity and PCOS and are of importance for dyslipidemia, hyperinsulinemia, and glucose intolerance in these conditions. In particular, a decreased lipolytic effect of catecholamines in adipose tissue has been repeatedly demonstrated in obesity and has been suggested as a cause of excess accumulation of body fat (28,29). Our data on lipolysis are, at least in part, in contrast with the prevalent idea that adipocytes from visceral fat depots are thought to be hyperlipolytic. Nevertheless, relatively few studies have directly compared lipolysis in visceral versus subcutaneous adipocytes or adipose tissues, with no unanimous findings. Moreover, although several determinants, such as polymorphisms of β-adrenergic receptor and its level of expression (30,31) and/or reduced expression and activity of adipocyte hormone-sensitive and trilglycercide lipases (32,33) have been proposed as responsible for the lipolytic catecholamine resistance in obesity, the mechanisms of this defect have not been fully understood. We now propose that differences in PKA expression and function, which interestingly were particularly evident in the visceral adipose tissue, may be included among the complex and multiple players that cause fat accumulation or mobilization by reducing catecholamine signaling.

In conclusion, our study indicates that, as in mice, R2B is the key PKA regulatory subunit in human adipose tissue, both in obese and normal subjects, with no significant differences between visceral and subcutaneous adipose tissue. Moreover, R2B was dramatically reduced in adipo-
cytes from obese patients, with a significant negative correlation between R2B expression levels and BMI, waist circumference, insulin levels, and HOMA-IR. Accordingly, both basal and cAMP-stimulated PKA activity and glycerol release were significantly lower in adipocytes from obese patients in comparison with those from nonobese subjects. Our results indicate important BMI-related differences in R2B expression and PKA activation, which might be included among the multiple determinants involved in the different lipolytic response to β-adrenergic activation in obese and nonobese subjects.

ACKNOWLEDGMENTS

This work was supported by grant PRIN 2006060982_002 to A.S. and by Ricerca Corrente Funds of Fondazione Policlinico IRCCS, Milan.

No potential conflicts of interest relevant to this article were reported.

REFERENCES

1. Skalbeg B, Tasken K: Specificity in the cAMP/PKA signaling pathway: differential expression, regulation, and subcellular localization of subunits of PKA. Front Biosci 5:D678–D693, 2000

2. Cho-Chung YS: Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignancy: new approaches to therapy. Cancer Res 50:7093–7100, 1990

3. Tortora G, Clair T, Cho-Chung YS: An antisense oligodeoxynucleotide targeted against the type RII regulatory subunit mRNAs of protein kinase inhibits cAMP-induced differentiation in HL-60 leukemia cells without affecting phorbol ester effects. Proc Natl Acad Sci U S A 87:705–708, 1990

4. McKechnie GS, Cummings DE, Amieux PS, Sikorski MA, Brandon EP, Planas JV, Motamed K, Idzerda RL, McKnight GS: Genetically lean mice result from targeted disruption of the RII beta subunit of protein kinase A. Nature 382:622–626, 1996

5. Meier MK, Alig L, Burgi-Saville ME, Muller M: Phenethanolamine derivatives with calorigenic and antidiabetic qualities. Int J Obes Relat Metab Disord 28:R1371–R1382, 1994

6. Himms-Hagen J, Cui J, Danforth E Jr, Tatses DJ, Lang SS, Waters BL, Claus TH: Effect of CL-316,243, a thermogenic beta 3-agonist on energy balance and brown and white adipose tissues in rats. Am J Physiol 266:R1371–R1382, 1994

7. Largis EE, Burns MG, Meunkel HA, Dolan JA, Claus TH: Antidiabetic and antiobesity effects of a highly selective B3-adrenoceptor agonist. Drug Dev Res 23:69–76, 1991

8. Amieux PS, Cummings DE, Motamed K, Brandon EP, Wailis LA, Le K, Iderza RL, McKechnie GS: Compensatory regulation of RII protein levels in protein kinase A mutant mice. J Biol Chem 272:3993–3998, 1997

9. Ek I, Arner P, Rydén M, Holm C, Thörne A, Hoffstedt J, Wahrenberg H: A unique defect in the regulation of visceral fat cell lipolysis in the polycystic ovary syndrome as an early link to insulin resistance. Diabetes 51:484–492, 2002

10. Faubald G, Rydén M, Ek I, Wahrenberg H, Arner P: Mechanisms behind lipolytic catecholamine resistance of subcutaneous fat cells in the polycystic ovarian syndrome. J Clin Endocrinol Metab 88:2520–2525, 2003

11. Lania AG, Mantovani G, Ferrero S, Pellegrini C, Bondioni S, Peverelli E, Braidotti P, Locatelli M, Zavanone ML, Ferrante E, Bosari S, Beck-Peccoz P, Spada A: Proliferation of transformed somatotroph cells related to low or absent expression of PKA regulatory subunit 1A protein. Cancer Res 64:9193–9198, 2004

12. Mantovani G, Lania AG, Bondioni S, Peverelli E, Pedroni C, Ferrero S, Pellegrini C, Vicentini L, Arnaldi G, Bosari S, Beck-Peccoz P, Spada A: Different expression of protein kinase A (PKA) regulatory subunits in cortisol-secreting adrenocortical tumors: relationship with cell proliferation. Exp Cell Res 314:123–130, 2008

13. Alberti L, Girola A, Gilardini L, Conti A, Cattaldo S, Micheletto G, Invitti C: Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase 1 in obese subjects. Int J Obes 31:1826–1831, 2007

14. Planas JV, Cunnings DE, Iderza RL, McKechnie GS: Mutation of the RIIbeta subunit of protein kinase A differentially affects lipolysis but not gene induction in white adipose tissue. J Biol Chem 274:36281–36287, 1999

15. Schreyer SA, Cummings DE, McKechnie GS, LeBeouf RC: Mutation of the RIIbeta subunit of protein kinase A prevents diet-induced insulin resistance and dyslipidemia in mice. Diabetes 50:2555–2562, 2001

16. Nolos MA, Sikorski MA, McKechnie GS: The role of uncoupling protein 1 in the metabolism and adiposity of RII beta-protein kinase A-deficient mice. Mol Endocrinol 19:982–991, 2005

17. Ozyayta TA, Sikorski MA, Yang L, McKechnie GS: Disruption of the RII beta subunit of PKA reverses the obesity syndrome of Agouti lethal yellow mice. Proc Natl Acad Sci U S A 105:270–281, 2008

18. Mantovani G, Bondioni S, Lania AG, Rosolfo M, Peverelli E, Polentarutti N, Velza Rodriguez T, Ferrero S, Bosari S, Beck-Peccoz P, Spada A: High expression of PKA regulatory subunit 1A protein is related to proliferation of human melanoma cells. Oncogene 27:1834–1843, 2008

19. Van Harmelen V, Lonnqvist F, Thörne A, Wennhuld A, Large V, Reynoldsott F, Arner P: Noradrenaline-induced lipolysis in isolated mesenteric, omental and subcutaneous adipocytes from obese subjects. Int J Obes Relat Metab Disord 21:972–979, 1997

20. Mohantsy S, Lee S, Yadava N, Dealy MJ, Johnson RS, Firtel RA: Regulation of protein degradation controls PKA function and cell-type differentiation in Dictyostelium. Genes Dev 15:1435–1448, 2001

21. Clegg CH, Cadd GG, McKechnie GS: Genetic characterization of a brain-specific form of the type I regulatory subunit of cAMP-dependent protein kinase. Proc Natl Acad Sci U S A 85:3703–3707, 1988

22. Luo Z, Singh IS, Fujihira T, Erlichman J: Characterization of a minimal promoter element required for transcription of the mouse type II beta regulatory subunit (RII beta) of cAMP-dependent protein kinase. J Biol Chem 267:24738–24747, 1992

23. Hoffstedt J, Arner P, Hellsers G, Lonnqvist F: Variation in adrenergic regulation of lipolysis between omental and subcutaneous adipocytes from obese and non-obese men. J Lipid Res 38:795–804, 1997

24. Large V, Recynsodt S, Langin D, Fredby K, Kinnemark M, Holm C, Arner P: Decreased expression and function of adipocyte hormone-sensitive lipase in subcutaneous fat cells of obese subjects. J Lipid Res 40:2050–2066, 1999

25. Collins S, Daniel KW, Rolfs EM: Depression of adipocyte beta-adrenergic receptors is a common feature of congenital and diet-induced obesity in rodents. Int J Obes Relat Metab Disord 23:669–677, 1999

26. Collins S, Surwit RS: The beta-adrenergic receptors and the control of adipose tissue metabolism and thermogenesis. Recent Prog Horm Res 56:599–629, 2001

27. Robidoux J, Martin TL, Collins S: Beta-adrenergic receptors and regulation of energy expenditure: a family affair. Annu Rev Pharmacol Toxicol 44:297–323, 2004

28. Jocken JW, Blaak EE, Schuffelers S, Arner P, van Baak MA, Saris WH: Association of a beta2-adrenoceptor (ADRB2) gene variant with a blunted in vivo lipolysis and fat oxidation. Int J Obes (Lond) 31:181–189, 2007

29. Macho-Azarate T, Marti A, Gonzalez A, Martinez JA, Ibabe J: Gln27Glu polymorphism in the beta2 adrenergic receptor gene and lipid metabolism during exercise in obese women. Int J Obes Relat Metab Disord 26:1434–1441, 2002

30. Jocken JW, Langin D, Smit E, Saris WH, Vallee C, Hol GB, Holm C, Arner P, Blaak EE: Adipocyte triglyceride lipase and hormone-sensitive lipase protein expression is decreased in the obese insulin-resistant state. J Clin Endocrinol Metab 92:2292–2296, 2007

31. Steinberg GR, Kemp BE, Watt MJ: Adipocyte triglyceride lipase expression in human obesity. Am J Physiol Endocrinol Metab 293:E958–E964, 2007